RANDY KARU: Open Payments
NPI 1386645760 · POMONA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,852 in 54 payments from 16 companies in 2025. Trend: 2023 $2,670 · 2024 $1,967 · 2025 $1,852
Food & beverage: $1,852
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $679 |
| AstraZeneca Pharmaceuticals LP | 12 | $602 |
| Otsuka America Pharmaceutical, Inc. | 4 | $192 |
| Merck Sharp & Dohme LLC | 3 | $69 |
| GlaxoSmithKline, LLC. | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $33 |
| ABBVIE INC. | 1 | $28 |
| Novo Nordisk Inc | 1 | $27 |
| Ardelyx, Inc. | 1 | $23 |
| Exact Sciences Corporation | 1 | $21 |
Products named: CAPLYTA, AIRSUPRA, FARXIGA, REXULTI, VERQUVO, TRELEGY ELLIPTA, Kerendia, LINZESS.
Industry payments across CA — which companies pay providers there.
